PharmaFocus Today – Page 31 – media

Zhengda Tianqing targets 9.2 billion yuan drug

On September 15, the injectable degarelix acetate (Qinglishu) independently developed by Zhengda Tianqing obtained the drug registration certificate issued by the National Medical Products Administration (NMPA) for use in prostate cancer patients who require androgen deprivation therapy. As the original drug in this category, degarelix acetate (fermonger)’s global sales exceeded US$1.3 billion (approximately RMB 9.2 billion) in 2024. Is Zhengda Tianqing, the “pioneer in anti-tumor innovation”, brewing a blockbuster drug? 01 Approved for listing in three locations The original developer of Degarelix Acetate for Injection is Ferring Pharmaceuticals. As a selective gonadotropin-releasing hormone receptor (GnRHR) antagonist, the clinical value of Degarelix Acetate in the treatment of prostate cancer has long been recognized worldwide. This drug can effectively reduce the release of gonadotropin and testosterone by reversibly binding to the GnRH receptors in the pituitary gland, thereby inhibiting the growth and spread of prostate cancer cells from the root. Especially in ...
- Source: drugdu
- 186
- September 18, 2025
Announcement on the Holding Subsidiary Obtaining Medical Device Registration Certificate

September 17th, Meikang BioAccording to the announcement, the company’s holding subsidiary Jiangxi Meikang Shengde Biotechnology Co., Ltd. recently obtained the ” Medical Device Certificate of the People’s Republic of China” issued by the Jiangxi Provincial Drug Administration.Registration Certificate ( In Vitro DiagnosticThe product names are: tissue plasminogen activator-inhibitor 1 complex detection kit (chemiluminescent immunoassay), thrombin-antithrombin complex detection kit (chemiluminescent immunoassay), thrombomodulin detection kit (chemiluminescent immunoassay), plasmin-α2 plasmin inhibitor complex detection kit (chemiluminescent immunoassay). https://finance.eastmoney.com/a/202509173516207639.html
- Source: drugdu
- 112
- September 18, 2025
Plans to invest RMB 42.74 million in Wuhan Huajiyuan to advance clinical trials of the therapeutic antihypertensive vaccine (HJY-ATRQβ-001) project

Meijing AI News, September 17, Saili Medical(603716.SH) announced plans to increase capital by 42.7429 million yuan in its subsidiary, Wuhan Huajiyuan Biotechnology Development Co., Ltd. Upon completion of the capital increase, the company’s stake in Wuhan Huajiyuan will increase to 41%. Concurrently, the company’s actual controller, Wen Wei, plans to acquire a 10% stake in Wuhan Huajiyuan shareholder Sun Danping for 27.2 million yuan, at a post-capital valuation of 272 million yuan. The company and its actual controller, Wen Wei, will contribute a total of 69.9429 million yuan in this transaction. The target company will be consolidated as a controlled subsidiary of the company in 2026. All parties agreed to actively advance the various phases of clinical trials for the target company’s therapeutic antihypertensive vaccine (HJY-ATRQβ-001) project and work together to develop the target company’s business. Upon completion of the capital increase, all parties pledged to actively conduct research and ...
- Source: drugdu
- 113
- September 18, 2025
Eli Lilly wins again! Oral weight loss drug outperforms oral sirolimus in head-to-head tria

Eli LillyTwo star weight loss pillsThe “one-on-one” battle has spread to the field of oral drugs, and the pressure has been put on Novo Nordisk.. On September 17, Eli Lilly announced positive top-line results from the Phase III ACHIEVE-3 study. The 52-week study compared orforglipron (12 mg and 36 mg) with oral semaglutide (7 mg and 14 mg) in terms of glycemic control and weight loss across four active treatment groups. At 52 weeks, orforglipron achieved its primary endpoint and all key secondary endpoints across all dose groups, demonstrating superiority over oral semaglutide in terms of improvements in glycated hemoglobin (A1C) and weight. Orforglipron is an oral small molecule GLP-1 receptor agonist from Eli Lilly , and Rybelsus is an oral GLP-1 drug from Novo Nordisk . The aforementioned study was a head-to-head comparison. A head-to-head study can be considered a direct comparison of the two drugs’ efficacy and safety. ...
- Source: drugdu
- 150
- September 18, 2025
Hengrui’s breakthrough hepatitis B therapy arrives

On September 15, the CDE official website announced that Hengrui Medicine’s new generation of liver-targeted hepatitis B virus siRNA drug HRS-5635 injection is planned to be included in the breakthrough therapy variety for the treatment of chronic hepatitis B. Chronic hepatitis B (CHB) is a chronic inflammatory liver disease caused by persistent infection with the hepatitis B virus (HBV). According to the World Health Organization, 254 million people worldwide were living with chronic HBV infection in 2022, with approximately 1.2 million new infections. In China, a major country with a high incidence of CHB, epidemiological data from 2020 estimated that there were approximately 75 million HBV carriers, of whom approximately 30 million were infected but unaware. Of those diagnosed, 17 million required antiviral treatment, but only 3 million received it. In addition, HBV infection significantly increases the risk of developing cirrhosis and liver cancer. The proportion of cirrhosis and liver ...
- Source: drugdu
- 233
- September 17, 2025
Progress in ASC30 Research

On September 17, Ascletis Pharma-B (01672) issued an announcement, announcing that it reported the results of a 28-day multiple-dose escalation study of its ASC30 oral small molecule GLP-1R agonist at the 61st European Association for the Study of Diabetes Annual Meeting held in Vienna, Austria on September 16, 2025. In MAD Cohort 2, once-daily oral administration of ASC30 demonstrated a placebo-adjusted mean weight loss of 6.5% from baseline after 28 days of treatment, compared to a mean weight loss of 4.5% in MAD Cohort 1. The study was well-safe and well-tolerated, with only mild to moderate gastrointestinal adverse events and no serious adverse events. https://finance.eastmoney.com/a/202509173515879467.html
- Source: drugdu
- 91
- September 17, 2025
Sabin strain inactivated polio vaccine approved for marketing, enriching product portfolio

　　China Securities Intelligence Financial News Kangtai Biological(300601) announced on the evening of September 15 that its wholly-owned subsidiary Beijing Minhai Biotechnology Co., Ltd. received the “Drug Registration Certificate” issued by the State Food and Drug Administration, and its developed Sabin strain inactivated polio vaccine (Vero cell) was officially approved for marketing. 　　According to the announcement, the vaccine is used to prevent acute infectious diseases caused by polio virus. After vaccination, it can stimulate the body to produce immunity against polio virus and is used to prevent poliomyelitis caused by polio type I, II and III virus infection. 　　According to the website of the National Medical Products Administration, the manufacturers of the vaccine currently on the market in China include Beijing Sinovac BiotechProducts Co., Ltd., Beijing Biological ProductsInstitute Co., Ltd., Institute of Medical Biology, Chinese Academy of Medical Sciences. 　　The announcement stated that the approval of the above-mentioned vaccines for marketing ...
- Source: drugdu
- 114
- September 17, 2025
Borrui Pharmaceuticals’ application for clinical trial of BGM0504 tablets in overweight/obese adults has been approved.

Borrui Pharmaceuticals(688166) announced on the evening of September 15th that its wholly-owned subsidiary, Borrui Pharmaceutical, recently received a “Notice of Approval for Drug Clinical Trial” from the National Medical Products Administration (NMPA), authorizing the clinical trial of Borrui Pharmaceutical’s BGM0504 tablets in overweight/obese adults. BGM0504 is a dual agonist of the GLP-1 (glucagon-like peptide 1) and GIP (glucose-dependent insulinotropic polypeptide) receptors independently developed by the company. It activates the downstream pathways of GIP and GLP-1, resulting in biological effects such as blood sugar control, weight loss, and the treatment of non-alcoholic steatohepatitis (NASH), demonstrating potential for the treatment of various metabolic diseases. BGM0504 injection is currently in Phase III clinical trials in China for both type 2 diabetes and weight loss. BGM0504 tablets are the oral formulation of BGM0504. As of the date of this announcement, no oral formulations targeting this target have been approved for marketing globally. https://finance.eastmoney.com/a/202509153513828386.html
- Source: drugdu
- 121
- September 17, 2025
Novo Nordisk’s Rybelsus Becomes First EU Approved Oral GLP-1 Reducing Severe Cardiovascular Events

Novo Nordisk announced the European Medicines Agency’s Committee for Medicinal Products for Human Use approved an update for Rybelsus’ label now displaying its cardiovascular benefits discovered in the Phase 3b SOUL trial. “Heart problems are the leading cause of disability and death for people living with type 2 diabetes. Therefore, treatments that also address heart problems are key to improving not only health outcomes, but also quality of life, and this approval will help do just that,” said Emil Kongshøj Larsen, executive vice president, international operations at Novo Nordisk. Larsen continued, saying,“This milestone makes semaglutide the only oral GLP-1 RA with proven blood glucose and body weight reduction, as well as cardiovascular benefits.” Rybelsus’ next steps Novo Nordisk is planning on sharing the full results from the GLP-1’s Phase 3b SOUL trial later this week at the European Association for the Study of Diabetes’ (EASD) 2025 Annual Meeting, running from ...
- Source: drugdu
- 124
- September 17, 2025
Triple Dose Of Ozempic Safe, More Effective For Weight Loss

By Dennis Thompson HealthDay ReporterTUESDAY, Sept. 16, 2025 (HealthDay News) — A triple-sized weekly dose of Ozempic works better to help people with obesity shed excess pounds without significant side effects, new clinical trial results show. Obese folks lost more weight taking 7.2 mg of semaglutide (Ozempic/Wegovy) a week than those taking either the currently approved dose of 2.4 mg or a placebo, researchers reported Sept. 14 in The Lancet Diabetes & Endocrinology. The results “suggest that a higher dose of semaglutide up to 7.2 mg per week could be used to achieve greater clinical benefits in people not reaching therapeutic goals with once-weekly semaglutide 2.4 mg,” concluded a team led by Dr. Sean Wharton, leader of the Wharton Medical Clinic for Weight and Diabetes Management in Ontario, Canada. Researchers tested the triple-dose of semaglutide in two clinical trials, one involving people with obesity and the other in people with ...
- Source: drugdu
- 106
- September 17, 2025

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.